JP2021523232A5 - - Google Patents

Info

Publication number
JP2021523232A5
JP2021523232A5 JP2021513015A JP2021513015A JP2021523232A5 JP 2021523232 A5 JP2021523232 A5 JP 2021523232A5 JP 2021513015 A JP2021513015 A JP 2021513015A JP 2021513015 A JP2021513015 A JP 2021513015A JP 2021523232 A5 JP2021523232 A5 JP 2021523232A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
conjugate according
antibody conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513015A
Other languages
English (en)
Japanese (ja)
Other versions
JP7459063B2 (ja
JP2021523232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000577 external-priority patent/WO2019215510A2/en
Publication of JP2021523232A publication Critical patent/JP2021523232A/ja
Publication of JP2021523232A5 publication Critical patent/JP2021523232A5/ja
Priority to JP2024006265A priority Critical patent/JP7771235B2/ja
Application granted granted Critical
Publication of JP7459063B2 publication Critical patent/JP7459063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513015A 2018-05-09 2019-05-09 抗-cd19抗体薬物複合体に関連する組成物および方法 Active JP7459063B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024006265A JP7771235B2 (ja) 2018-05-09 2024-01-18 抗-cd19抗体薬物複合体に関連する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669183P 2018-05-09 2018-05-09
US62/669,183 2018-05-09
PCT/IB2019/000577 WO2019215510A2 (en) 2018-05-09 2019-05-09 Compositions and methods related to anti-cd19 antibody drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024006265A Division JP7771235B2 (ja) 2018-05-09 2024-01-18 抗-cd19抗体薬物複合体に関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2021523232A JP2021523232A (ja) 2021-09-02
JP2021523232A5 true JP2021523232A5 (enExample) 2022-05-17
JP7459063B2 JP7459063B2 (ja) 2024-04-01

Family

ID=68467325

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513015A Active JP7459063B2 (ja) 2018-05-09 2019-05-09 抗-cd19抗体薬物複合体に関連する組成物および方法
JP2024006265A Active JP7771235B2 (ja) 2018-05-09 2024-01-18 抗-cd19抗体薬物複合体に関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024006265A Active JP7771235B2 (ja) 2018-05-09 2024-01-18 抗-cd19抗体薬物複合体に関連する組成物および方法

Country Status (13)

Country Link
US (3) US11827703B2 (enExample)
EP (1) EP3790591A4 (enExample)
JP (2) JP7459063B2 (enExample)
KR (1) KR20210023839A (enExample)
CN (1) CN112601555A (enExample)
AU (2) AU2019266406B2 (enExample)
BR (1) BR112020022299A2 (enExample)
CA (1) CA3099680A1 (enExample)
IL (1) IL278480B2 (enExample)
MX (1) MX421450B (enExample)
SG (1) SG11202010443WA (enExample)
TW (1) TWI859138B (enExample)
WO (1) WO2019215510A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ, インク. ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
US11827703B2 (en) * 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
US20230139328A1 (en) * 2020-03-12 2023-05-04 Aphios Corporation Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants
AU2021251875A1 (en) * 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
KR20220142393A (ko) * 2021-04-14 2022-10-21 주식회사 레고켐 바이오사이언스 단백질 분해제 접합체 및 이의 용도
KR20240028449A (ko) * 2021-06-29 2024-03-05 에이디씨 테라퓨틱스 에스에이 항체-약물 접합체를 이용한 병용 요법
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
KR20250175329A (ko) * 2023-04-27 2025-12-16 바이오아트라, 인코퍼레이티드 약물 접합체 및 항체 약물 접합체용 링커
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
CN118341125B (zh) * 2024-04-19 2026-07-03 华域生物科技(天津)有限公司 富集外泌体的方法及该方法所采用的缀合物
WO2026085538A1 (en) * 2024-10-18 2026-04-23 Conveyor Therapeutics, Inc. Antibody drug conjugates
CN120249221B (zh) * 2025-04-14 2025-12-02 北京壹拾智检生物科技有限公司 一种杂交瘤细胞及呋喃妥因代谢物的检测方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112739A (en) 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
DK0795334T3 (da) 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
EP0941120A4 (en) 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
JP2006510626A (ja) 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2578131A1 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
CN101287500A (zh) 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
WO2008112004A2 (en) * 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2008034120A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
ZA200902161B (en) 2006-10-27 2010-06-30 Genentech Inc Antiobodies and immunoconjugates and uses therefor
WO2008056833A1 (en) 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP5404624B2 (ja) 2007-08-01 2014-02-05 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ[2,1−c][1,4]ベンゾジアゼピン−グリコシドプロドラッグ
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
WO2009116670A1 (ja) 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
US9591882B2 (en) 2010-08-05 2017-03-14 Robert LaGrand Duffin Absorbent sleeve
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
KR20120107741A (ko) 2011-03-22 2012-10-04 한국생명공학연구원 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법
WO2012138102A2 (ko) 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
KR101461706B1 (ko) 2011-04-04 2014-11-18 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
CN103502990A (zh) 2011-04-29 2014-01-08 惠普发展公司,有限责任合伙企业 用于事件的内存中处理的系统和方法
DK2707031T3 (da) 2011-05-08 2019-10-07 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP2800586A1 (en) 2012-01-03 2014-11-12 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
HK1219044A1 (zh) 2013-03-15 2017-03-24 艾伯维德国有限责任两合公司 抗egfr抗体药物偶联物制剂
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015052533A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
ES2729643T3 (es) 2013-11-26 2019-11-05 Novartis Ag Métodos para la conjugación de oxima con polipéptidos modificados con cetona
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
JP2018502839A (ja) 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
KR20160080832A (ko) 2014-12-29 2016-07-08 주식회사 레고켐 바이오사이언스 리피바디 유도체-약물 복합체, 그 제조방법 및 용도
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CN114716506A (zh) 2015-01-30 2022-07-08 苏特罗生物制药公司 用于偶联和治疗的哈米特林(hemiasterlin)衍生物
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
WO2017051249A1 (en) * 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
SG11201803054UA (en) * 2015-10-13 2018-05-30 Eureka Therapeutics Inc Antibody agents specific for human cd19 and uses thereof
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
CN107847605B (zh) * 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
RU2651776C2 (ru) 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3040812A1 (en) * 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ, インク. ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
TWI804499B (zh) 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
KR20190018400A (ko) 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
WO2019050362A2 (ko) 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
KR20200084802A (ko) 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
JP7664045B2 (ja) 2019-03-06 2025-04-17 リガケム バイオサイエンシズ, インク. ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
CN110784759B (zh) 2019-08-12 2022-08-12 腾讯科技(深圳)有限公司 弹幕信息处理方法、装置、电子设备及存储介质
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP7771235B2 (ja) 抗-cd19抗体薬物複合体に関連する組成物および方法
JP2023531252A5 (enExample)
JP2022522547A5 (enExample)
JP7381478B2 (ja) 単一分子量ポリサルコシンを含むリガンド-薬物-複合体
JP7583460B2 (ja) 抗体-薬物コンジュゲート
CN113710277B (zh) 一种负载双毒素的抗体药物偶联物及其应用
JP2019503980A5 (enExample)
HRP20240795T1 (hr) Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
ES2361096T3 (es) Procedimiento para fijar moléculas efectoras a proteínas.
US20230295346A1 (en) Prodruggable antibodies, prodrugs thereof, and methods of use and making
EP4321180A1 (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
JP2019503981A5 (enExample)
JP7664045B2 (ja) ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
JP2019503979A5 (enExample)
CN120076831A (zh) 抗ror1抗体和抗体缀合物、包含抗ror1抗体或抗体缀合物的组合物、以及制备和使用抗ror1抗体和抗体缀合物的方法
JP2023500875A5 (enExample)
JP2026510495A (ja) ヒトl1camに対する抗体を含む抗体-薬物コンジュゲートおよびその使用
JP2019525727A (ja) 新規の抗tnfrsf21抗体及び使用方法
JP2025511705A5 (enExample)
ES2382879T3 (es) Conjugado de anticuerpo - polímero de peine.
RU2021128538A (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
RU2801630C2 (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
TWI899083B (zh) 包含針對人dlk1的抗體的抗體藥物偶聯物及其用途
RU2020140202A (ru) Композиции и способы, относящиеся к конъюгатам лекарственных средств с антителами против cd19
TW202344271A (zh) 包含針對人cldn18.2的抗體的抗體藥物偶聯物及其用途